State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent
Cancer ranks as the first leading cause of death globally. Despite the various types of cancer treatments, negative aspects of the treatments, such as side effects and drug resistance, have been a continuous dilemma for patients. Thus, natural compounds and herbal medicines have earned profound inte...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/4/1089 |
| _version_ | 1797482045267509248 |
|---|---|
| author | Kangwook Lee Bo-Young Youn Yu-Jeong Choi Seunghwan Moon Jungkwun Im Kyongha Cho Seong-Gyu Ko Chunhoo Cheon |
| author_facet | Kangwook Lee Bo-Young Youn Yu-Jeong Choi Seunghwan Moon Jungkwun Im Kyongha Cho Seong-Gyu Ko Chunhoo Cheon |
| author_sort | Kangwook Lee |
| collection | DOAJ |
| description | Cancer ranks as the first leading cause of death globally. Despite the various types of cancer treatments, negative aspects of the treatments, such as side effects and drug resistance, have been a continuous dilemma for patients. Thus, natural compounds and herbal medicines have earned profound interest as chemopreventive agents for reducing burden for patients. SH003, a novel herbal medicine containing Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii, showed the potential to act as an anticancer agent in previous research studies. A narrative review was conducted to present the significant highlights of the total 15 SH003 studies from the past nine years. SH003 has shown positive results in both in vivo and vitro studies against various types of cancer cells; furthermore, the first clinical trial was performed to identify the maximum tolerated dose among solid cancer patients. So far, the potential of SH003 as a chemotherapeutic agent has been well-documented in research studies; continuous work on SH003’s efficacy and safety is required to facilitate better cancer patient care but is part of the knowledge needed to understand whether SH003 has the potential to become a pharmaceutical. |
| first_indexed | 2024-03-09T22:23:41Z |
| format | Article |
| id | doaj.art-fa10856b7c0348ab835d6e774e30dfe4 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:23:41Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-fa10856b7c0348ab835d6e774e30dfe42023-11-23T19:11:12ZengMDPI AGCancers2072-66942022-02-01144108910.3390/cancers14041089State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer AgentKangwook Lee0Bo-Young Youn1Yu-Jeong Choi2Seunghwan Moon3Jungkwun Im4Kyongha Cho5Seong-Gyu Ko6Chunhoo Cheon7Department of Preventive Medicine, Kyung Hee University, Seoul 02447, KoreaDepartment of Preventive Medicine, Kyung Hee University, Seoul 02447, KoreaDepartment of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, KoreaDepartment of Global Public Health and Korean Medicine Management, Graduate School, Kyung Hee University, Seoul 02447, KoreaDepartment of Global Public Health and Korean Medicine Management, Graduate School, Kyung Hee University, Seoul 02447, KoreaDepartment of Global Public Health and Korean Medicine Management, Graduate School, Kyung Hee University, Seoul 02447, KoreaDepartment of Preventive Medicine, Kyung Hee University, Seoul 02447, KoreaDepartment of Preventive Medicine, Kyung Hee University, Seoul 02447, KoreaCancer ranks as the first leading cause of death globally. Despite the various types of cancer treatments, negative aspects of the treatments, such as side effects and drug resistance, have been a continuous dilemma for patients. Thus, natural compounds and herbal medicines have earned profound interest as chemopreventive agents for reducing burden for patients. SH003, a novel herbal medicine containing Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii, showed the potential to act as an anticancer agent in previous research studies. A narrative review was conducted to present the significant highlights of the total 15 SH003 studies from the past nine years. SH003 has shown positive results in both in vivo and vitro studies against various types of cancer cells; furthermore, the first clinical trial was performed to identify the maximum tolerated dose among solid cancer patients. So far, the potential of SH003 as a chemotherapeutic agent has been well-documented in research studies; continuous work on SH003’s efficacy and safety is required to facilitate better cancer patient care but is part of the knowledge needed to understand whether SH003 has the potential to become a pharmaceutical.https://www.mdpi.com/2072-6694/14/4/1089anticancer agentcancernatural compoundphytochemicalherbal medicine |
| spellingShingle | Kangwook Lee Bo-Young Youn Yu-Jeong Choi Seunghwan Moon Jungkwun Im Kyongha Cho Seong-Gyu Ko Chunhoo Cheon State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent Cancers anticancer agent cancer natural compound phytochemical herbal medicine |
| title | State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent |
| title_full | State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent |
| title_fullStr | State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent |
| title_full_unstemmed | State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent |
| title_short | State of the Art and Future Implications of SH003: Acting as a Therapeutic Anticancer Agent |
| title_sort | state of the art and future implications of sh003 acting as a therapeutic anticancer agent |
| topic | anticancer agent cancer natural compound phytochemical herbal medicine |
| url | https://www.mdpi.com/2072-6694/14/4/1089 |
| work_keys_str_mv | AT kangwooklee stateoftheartandfutureimplicationsofsh003actingasatherapeuticanticanceragent AT boyoungyoun stateoftheartandfutureimplicationsofsh003actingasatherapeuticanticanceragent AT yujeongchoi stateoftheartandfutureimplicationsofsh003actingasatherapeuticanticanceragent AT seunghwanmoon stateoftheartandfutureimplicationsofsh003actingasatherapeuticanticanceragent AT jungkwunim stateoftheartandfutureimplicationsofsh003actingasatherapeuticanticanceragent AT kyonghacho stateoftheartandfutureimplicationsofsh003actingasatherapeuticanticanceragent AT seonggyuko stateoftheartandfutureimplicationsofsh003actingasatherapeuticanticanceragent AT chunhoocheon stateoftheartandfutureimplicationsofsh003actingasatherapeuticanticanceragent |